Company intelligence / Profile preview

PhageNova Bio

Summit, New Jersey, United Statesphagenovabio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

PhageNova Bio is a preclinical-stage biotechnology company developing a proprietary, first-in-class targeted gene expression technology. Their lead asset, PNB‑001, is in IND-enabling studies for solid tumors. The company also has a phage-based vaccination platform targeting COVID‑19 in preclinical evaluation. No clinical results have been reported as of May 2025.[1][3][6]

Therapeutic areas: OncologyInfectious Diseases
Modalities: Gene therapy (targeted gene expression)Prophylactic vaccine (phage-based vaccination)[1][7]
Industry: Biotech

Drug pipeline

1 asset

PNB-003

Preclinical

Partnerships

Partnered with leading biologic CDMO/CMO for manufacturing; no major pharma partnerships disclosed as of May 2025.[1]

Beyond the preview

Go deeper on PhageNova Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PhageNova Bio.

Explore the full profile